Cytogenetic abnormalities sufficient to diagnose AML with myelodysplasia-related changes when ≥20% PB or BM blasts are present and prior therapy has been excluded
| Cytogenetic abnormalities . |
|---|
| Complex karyotype (3 or more abnormalities) |
| Unbalanced abnormalities |
| −7/del(7q) |
| del(5q)/t(5q) |
| i(17q)/t(17p) |
| −13/del(13q) |
| del(11q) |
| del(12p)/t(12p) |
| idic(X)(q13) |
| Balanced abnormalities |
| t(11;16)(q23.3;p13.3) |
| t(3;21)(q26.2;q22.1) |
| t(1;3)(p36.3;q21.2) |
| t(2;11)(p21;q23.3) |
| t(5;12)(q32;p13.2) |
| t(5;7)(q32;q11.2) |
| t(5;17)(q32;p13.2) |
| t(5;10)(q32;q21.2) |
| t(3;5)(q25.3;q35.1) |
| Cytogenetic abnormalities . |
|---|
| Complex karyotype (3 or more abnormalities) |
| Unbalanced abnormalities |
| −7/del(7q) |
| del(5q)/t(5q) |
| i(17q)/t(17p) |
| −13/del(13q) |
| del(11q) |
| del(12p)/t(12p) |
| idic(X)(q13) |
| Balanced abnormalities |
| t(11;16)(q23.3;p13.3) |
| t(3;21)(q26.2;q22.1) |
| t(1;3)(p36.3;q21.2) |
| t(2;11)(p21;q23.3) |
| t(5;12)(q32;p13.2) |
| t(5;7)(q32;q11.2) |
| t(5;17)(q32;p13.2) |
| t(5;10)(q32;q21.2) |
| t(3;5)(q25.3;q35.1) |